Form 8-K - Current report:
SEC Accession No. 0001193125-25-019257
Filing Date
2025-02-03
Accepted
2025-02-03 16:02:29
Documents
13
Period of Report
2025-01-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d924316d8k.htm   iXBRL 8-K 23835
  Complete submission text file 0001193125-25-019257.txt   148643

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20250130.xsd EX-101.SCH 2834
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20250130_lab.xml EX-101.LAB 18756
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20250130_pre.xml EX-101.PRE 11699
15 EXTRACTED XBRL INSTANCE DOCUMENT d924316d8k_htm.xml XML 3782
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 25582446
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)